Introduction: RA treatment has been revolutionized by the development and approval of biologic disease-modifying antirheumatic drugs (bDMARDs). However, the approval status, utilization, and high cost of bDMARDs pose challenges in RA management.
Objectives: This dissertation evaluated the association between the utilization of bDMARDs and the sociodemographic characteristics of the RA patient population. It also identified the FDA approval status of bDMARDs and assessed the annual cost of bDMARDs used in RA treatment, evaluated the factors explaining annual cost at market entry.
Methods: In the retrospective analysis of Medical Expenditure Panel Survey (MEPS) data from 2010-2021, the population includes RA patients diagnosed using International Classification of Disease (ICD-9 and ICD-10). We used descriptive statistics, chi-square test, and logistic regression. Regulatory information and wholesale acquisition cost (WAC) for bDMARDs were extracted from the FDA and Micromedex. The bDMARD annual treatment cost was estimated using WAC prices at market entry and the FDA recommended dose. We standardized costs to evaluate trends within each group.
Results: We found that 5.2% of RA patients used bDMARDs from 2010-2021 in the MEPS sample. bDMARDs utilization was significantly associated with age, insurance coverage, and education level. While younger patients with private insurance and higher education were more likely to use bDMARDs therapy, factors such as sex, race, marital status, and employment status do not significantly influence treatment choices.
As of December 31, 2023, the FDA had approved ten bDMARDs for RA treatment in US, five of which were in the TNFi classification, and authorized 19 biosimilars for five bDMARDs. After standardization, the trend revealed a significant increase in the costs of TNFi bDMARDs and a substantial decrease following FDA authorization of biosimilars for infliximab, rituximab, and adalimumab. The annual cost at market entry was significantly positively correlated with FDA approval dates and TNFi classification.
Conclusions: The multifaceted nature of biologic therapy in RA management emphasizes the importance of comprehensively understanding the interplay between approvals, utilization, and cost to enhance treatment outcomes and healthcare delivery. Therefore, addressing these factors is important to ensure that all individuals with RA can benefit from these transformative therapies.
","abstract_html":"<p><strong>Introduction:</strong> RA treatment has been revolutionized by the development and approval of biologic disease-modifying antirheumatic drugs (bDMARDs). However, the approval status, utilization, and high cost of bDMARDs pose challenges in RA management.</p> <p><strong>Objectives:</strong> This dissertation evaluated the association between the utilization of bDMARDs and the sociodemographic characteristics of the RA patient population. It also identified the FDA approval status of bDMARDs and assessed the annual cost of bDMARDs used in RA treatment, evaluated the factors explaining annual cost at market entry.</p> <p><strong>Methods: </strong>In the retrospective analysis of Medical Expenditure Panel Survey (MEPS) data from 2010-2021, the population includes RA patients diagnosed using International Classification of Disease (ICD-9 and ICD-10). We used descriptive statistics, chi-square test, and logistic regression. Regulatory information and wholesale acquisition cost (WAC) for bDMARDs were extracted from the FDA and Micromedex. The bDMARD annual treatment cost was estimated using WAC prices at market entry and the FDA recommended dose. We standardized costs to evaluate trends within each group.</p> <p><strong>Results: </strong>We found that 5.2% of RA patients used bDMARDs from 2010-2021 in the MEPS sample. bDMARDs utilization was significantly associated with age, insurance coverage, and education level. While younger patients with private insurance and higher education were more likely to use bDMARDs therapy, factors such as sex, race, marital status, and employment status do not significantly influence treatment choices.</p> <p>As of December 31, 2023, the FDA had approved ten bDMARDs for RA treatment in US, five of which were in the TNFi classification, and authorized 19 biosimilars for five bDMARDs. After standardization, the trend revealed a significant increase in the costs of TNFi bDMARDs and a substantial decrease following FDA authorization of biosimilars for infliximab, rituximab, and adalimumab. The annual cost at market entry was significantly positively correlated with FDA approval dates and TNFi classification.</p> <p><strong>Conclusions: </strong>The multifaceted nature of biologic therapy in RA management emphasizes the importance of comprehensively understanding the interplay between approvals, utilization, and cost to enhance treatment outcomes and healthcare delivery. Therefore, addressing these factors is important to ensure that all individuals with RA can benefit from these transformative therapies.</p>","abstract_has_math":false,"creators":["Hosseini, Roya"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation","degree_discipline":"Pharmaceutical Sciences","degree_department":null,"school":null,"contributors":["Enrique Seoane-Vazquez, PhD","Lawrence Brown, PharmD, PhD, FAPhA","Rosa Rodriguez-Monguio, PhD, MS","Marc L. Fleming, PhD, MPH, FAPhA"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-05-01T07:00:00Z","date_published":"2024-05-01T07:00:00Z","updated_at":"2026-07-24T01:38:37Z","subjects":["biologic disease-modifying antirheumatic drugs","bDMARDs","Rheumatoid Arthritis","Approvals","Utilization","Annual Cost","Pharmacoeconomics and Pharmaceutical Economics","Pharmacy Administration, Policy and Regulation"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.chapman.edu/pharmaceutical_sciences_dissertations/34","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Enrique Seoane-Vazquez, PhD","Lawrence Brown, PharmD, PhD, FAPhA","Rosa Rodriguez-Monguio, PhD, MS","Marc L. Fleming, PhD, MPH, FAPhA"]},{"key":"dc:creator","label":"Author","values":["Hosseini, Roya"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2026-05-31T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["biologic disease-modifying antirheumatic drugs","bDMARDs","Rheumatoid Arthritis","Approvals","Utilization","Annual Cost","Pharmacoeconomics and Pharmaceutical Economics","Pharmacy Administration, Policy and Regulation"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.chapman.edu/pharmaceutical_sciences_dissertations/34"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Introduction: RA treatment has been revolutionized by the development and approval of biologic disease-modifying antirheumatic drugs (bDMARDs). However, the approval status, utilization, and high cost of bDMARDs pose challenges in RA management.
Objectives: This dissertation evaluated the association between the utilization of bDMARDs and the sociodemographic characteristics of the RA patient population. It also identified the FDA approval status of bDMARDs and assessed the annual cost of bDMARDs used in RA treatment, evaluated the factors explaining annual cost at market entry.
Methods: In the retrospective analysis of Medical Expenditure Panel Survey (MEPS) data from 2010-2021, the population includes RA patients diagnosed using International Classification of Disease (ICD-9 and ICD-10). We used descriptive statistics, chi-square test, and logistic regression. Regulatory information and wholesale acquisition cost (WAC) for bDMARDs were extracted from the FDA and Micromedex. The bDMARD annual treatment cost was estimated using WAC prices at market entry and the FDA recommended dose. We standardized costs to evaluate trends within each group.
Results: We found that 5.2% of RA patients used bDMARDs from 2010-2021 in the MEPS sample. bDMARDs utilization was significantly associated with age, insurance coverage, and education level. While younger patients with private insurance and higher education were more likely to use bDMARDs therapy, factors such as sex, race, marital status, and employment status do not significantly influence treatment choices.
As of December 31, 2023, the FDA had approved ten bDMARDs for RA treatment in US, five of which were in the TNFi classification, and authorized 19 biosimilars for five bDMARDs. After standardization, the trend revealed a significant increase in the costs of TNFi bDMARDs and a substantial decrease following FDA authorization of biosimilars for infliximab, rituximab, and adalimumab. The annual cost at market entry was significantly positively correlated with FDA approval dates and TNFi classification.
Conclusions: The multifaceted nature of biologic therapy in RA management emphasizes the importance of comprehensively understanding the interplay between approvals, utilization, and cost to enhance treatment outcomes and healthcare delivery. Therefore, addressing these factors is important to ensure that all individuals with RA can benefit from these transformative therapies.
"]},{"key":"dc:source","label":"Dc Source","values":["Hosseini R., Approvals, Utilization, and Cost of Biologics for the Treatment of Rheumatoid Arthritis. [dissertation]. Irvine, CA: Chapman University; 2024. https://doi.org/10.36837/chapman.000570"]},{"key":"dc:title","label":"Title","values":["Approvals, Utilization, and Cost of Biologics for the Treatment of Rheumatoid Arthritis"]}]}],"canonical_facts":{"dc:contributor":["Enrique Seoane-Vazquez, PhD","Lawrence Brown, PharmD, PhD, FAPhA","Rosa Rodriguez-Monguio, PhD, MS","Marc L. Fleming, PhD, MPH, FAPhA"],"dc:creator":["Hosseini, Roya"],"dc:date.available":["2026-05-31T07:00:00Z"],"dc:description.abstract":["Introduction: RA treatment has been revolutionized by the development and approval of biologic disease-modifying antirheumatic drugs (bDMARDs). However, the approval status, utilization, and high cost of bDMARDs pose challenges in RA management.
Objectives: This dissertation evaluated the association between the utilization of bDMARDs and the sociodemographic characteristics of the RA patient population. It also identified the FDA approval status of bDMARDs and assessed the annual cost of bDMARDs used in RA treatment, evaluated the factors explaining annual cost at market entry.
Methods: In the retrospective analysis of Medical Expenditure Panel Survey (MEPS) data from 2010-2021, the population includes RA patients diagnosed using International Classification of Disease (ICD-9 and ICD-10). We used descriptive statistics, chi-square test, and logistic regression. Regulatory information and wholesale acquisition cost (WAC) for bDMARDs were extracted from the FDA and Micromedex. The bDMARD annual treatment cost was estimated using WAC prices at market entry and the FDA recommended dose. We standardized costs to evaluate trends within each group.
Results: We found that 5.2% of RA patients used bDMARDs from 2010-2021 in the MEPS sample. bDMARDs utilization was significantly associated with age, insurance coverage, and education level. While younger patients with private insurance and higher education were more likely to use bDMARDs therapy, factors such as sex, race, marital status, and employment status do not significantly influence treatment choices.
As of December 31, 2023, the FDA had approved ten bDMARDs for RA treatment in US, five of which were in the TNFi classification, and authorized 19 biosimilars for five bDMARDs. After standardization, the trend revealed a significant increase in the costs of TNFi bDMARDs and a substantial decrease following FDA authorization of biosimilars for infliximab, rituximab, and adalimumab. The annual cost at market entry was significantly positively correlated with FDA approval dates and TNFi classification.
Conclusions: The multifaceted nature of biologic therapy in RA management emphasizes the importance of comprehensively understanding the interplay between approvals, utilization, and cost to enhance treatment outcomes and healthcare delivery. Therefore, addressing these factors is important to ensure that all individuals with RA can benefit from these transformative therapies.
"],"dc:identifier":["https://digitalcommons.chapman.edu/pharmaceutical_sciences_dissertations/34"],"dc:source":["Hosseini R., Approvals, Utilization, and Cost of Biologics for the Treatment of Rheumatoid Arthritis. [dissertation]. Irvine, CA: Chapman University; 2024. https://doi.org/10.36837/chapman.000570"],"dc:subject":["biologic disease-modifying antirheumatic drugs","bDMARDs","Rheumatoid Arthritis","Approvals","Utilization","Annual Cost","Pharmacoeconomics and Pharmaceutical Economics","Pharmacy Administration, Policy and Regulation"],"dc:title":["Approvals, Utilization, and Cost of Biologics for the Treatment of Rheumatoid Arthritis"],"thesis:degree_discipline":["Pharmaceutical Sciences"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T01:38:37Z"}